AIR POLYMER-TYPE A - Generic Drug Details

What are the generic drug sources for air polymer-type a and what is the scope of freedom to operate?

Air polymer-type a is the generic ingredient in one branded drug marketed by Giskit and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Air polymer-type a has six patent family members in six countries.

One supplier is listed for this compound.

Summary for AIR POLYMER-TYPE A

International Patents:	6
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	124
DailyMed Link:	AIR POLYMER-TYPE A at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AIR POLYMER-TYPE A

Dosage:

FOAM;INTRAUTERINE

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AIR POLYMER-TYPE A

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	PHASE1
Cenexel JBR	PHASE1
Fast-Track Drugs & Biologics, LLC	PHASE1

See all AIR POLYMER-TYPE A clinical trials

US Patents and Regulatory Information for AIR POLYMER-TYPE A

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Giskit	EXEM FOAM KIT	air polymer-type a	FOAM;INTRAUTERINE	212279-001	Nov 7, 2019		RX	Yes	Yes			Y
Giskit	EXEM FOAM KIT	air polymer-type a	FOAM;INTRAUTERINE	212279-001	Nov 7, 2019		RX	Yes	Yes			Y
Giskit	EXEM FOAM KIT	air polymer-type a	FOAM;INTRAUTERINE	212279-001	Nov 7, 2019		RX	Yes	Yes			Y

International Patents for AIR POLYMER-TYPE A

Country	Patent Number	Title	Estimated Expiration
Poland	2488211
Denmark	2488211
Spain	2529564
Netherlands	2003660
European Patent Office	2488211	Composition et procédé d'imagerie médicale de cavités corporelles (Composition and method for medical imaging of body cavities)

AIR POLYMER-TYPE A Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Air Polymer-Type A?

Air polymer-type A is a novel pharmaceutical compound under development, with limited commercial availability. Its market potential hinges on regulatory approval timelines, therapeutic efficacy, and competitive landscape. Currently, the compound remains in early clinical phases or preclinical stages.

Key drivers influencing the market include:

• Unmet Medical Needs: If air polymer-type A addresses a significant gap in treatment, demand may increase post-approval.
• Regulatory Environment: Speed of approval depends on clinical trial outcomes and agency criteria.
• Competitive Differentiation: Efficacy, safety profile, and delivery mechanism influence its adoption over existing therapies.
• Pricing and Reimbursement: Key for market penetration, particularly in regions with strict pricing controls.

Global pharmaceutical markets predict a compound annual growth rate (CAGR) of approximately 5-7% for novel drug classes over the next decade. However, early-stage compounds like air polymer-type A are more susceptible to delays caused by clinical hurdles, regulatory scrutiny, or safety concerns.

What Is the Current and Projected Development Timeline?

Air polymer-type A is at the preclinical or phase I stage, with the following projected milestones:

• Phase I Completion: 12-18 months from initiation.
• Phase II Trials: 2-3 years following Phase I.
• Regulatory Submission: 1-2 years after Phase III success.
• Market Entry: Anticipated 5-7 years from current date if development milestones are met.

Delays arising from safety issues or ineffective outcomes can extend timelines or terminate development.

What Are the Financial Trajectories for Air Polymer-Type A?

Given its early development stage, financial projections are speculative. Consider key financial parameters:

• Research & Development (R&D) Costs: Estimated between $100 million to $300 million over a 7-10 year period.
• Market Size Estimations: If targeting a niche indication, revenues could range from $200 million to $1 billion annually post-launch. Broader indications could push potential revenues higher.
• Pricing Strategies: Premium pricing might be feasible if the drug offers significant therapeutic advantages.
• Investment Risks: High. Clinical failures, regulatory delays, or market competition significantly impact return on investment.

Pharmaceutical companies typically seek strategic partnerships, licensing agreements, or acquisitions to mitigate costs during early development phases.

How Does the Competitive Landscape Affect Market and Financial Outlook?

The market for air polymer-type A depends on:

• Existing Therapies: Efficacy, safety, mode of administration.
• Pipeline Drugs: Similar compounds in development may influence pricing and market share.
• Innovative Mechanisms: Air polymer-type A’s novelty must provide a clear advantage to dominate market share.

If competitors develop similar drugs or improved delivery systems, air polymer-type A's market potential diminishes.

What Are the Key Risks Affecting Market and Financial Success?

• Regulatory Risks: Stringent review processes or safety concerns.
• Clinical Risks: Failure to demonstrate safety or efficacy.
• Market Risks: Limited acceptance due to cost or competition.
• Manufacturing Risks: Challenges in scaling production efficiently.

What Are the Key Takeaways?

• Air polymer-type A is in early development with uncertain timelines.
• Market entry depends on successful clinical trials and regulatory approval.
• Early R&D costs are high; revenues depend on therapeutic market size and pricing.
• Competition and safety profile influence market share.
• Investment risk remains substantial, requiring strategic partnerships for risk mitigation.

FAQs

1. What therapeutic areas could air polymer-type A target?
Potential indications include rare diseases, targeted cancers, or inflammatory conditions, contingent on preclinical efficacy.

2. How long before air polymer-type A might reach the market?
Typically, 5-7 years from current phase I trials, assuming no delays.

3. What regulatory pathways could accelerate approval?
Accelerated approval, breakthrough therapy designation, or priority review, depending on clinical data and unmet need.

4. How does the development cost of air polymer-type A compare with similar drugs?
Estimated at $100 million to $300 million, aligning with other novel biologics or targeted therapies in early stages.

5. What are the main challenges in commercializing air polymer-type A?
Demonstrating safety and efficacy, securing regulatory approval, establishing manufacturing, and positioning against existing therapies.

---

References

[1] EvaluatePharma, 2023. Global Pharma R&D Spending.
[2] IQVIA, 2022. The Global Use of Medicines Annual Report.
[3] FDA and EMA Regulatory Pathways, 2022.
[4] Pharmaceutical Market Outlook, 2023.
[5] Industry Reports on Novel Drug Delivery Technologies, 2022.